A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC
- Conditions
- HIV Infections
- Registration Number
- NCT00002046
- Lead Sponsor
- Glaxo Wellcome
- Brief Summary
To evaluate the pharmacokinetics of Retrovir (AZT) administered orally as 1 of 3 doses in the treatment of patients with severe clinical and laboratory manifestations of HIV infection. To compare the safety and tolerance of AZT administered 2, 3, and 6 x daily to these patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (11)
Univ of Arizona / Health Science Ctr
🇺🇸Tucson, Arizona, United States
Northwestern Univ Med School
🇺🇸Chicago, Illinois, United States
Cook County Hosp
🇺🇸Chicago, Illinois, United States
Rush Presbyterian - Saint Luke's Med Ctr
🇺🇸Chicago, Illinois, United States
Johns Hopkins Hosp
🇺🇸Baltimore, Maryland, United States
Univ of Missouri at Kansas City School of Medicine
🇺🇸Kansas City, Missouri, United States
Univ of New Mexico Hlth Sciences Ctr / Dept of Med
🇺🇸Albuquerque, New Mexico, United States
Northshore Hosp / Cornell Univ
🇺🇸Manhasset, New York, United States
Univ of Pennsylvania / HIV Clinic
🇺🇸Philadelphia, Pennsylvania, United States
Univ TX Galveston Med Branch
🇺🇸Galveston, Texas, United States
Scroll for more (1 remaining)Univ of Arizona / Health Science Ctr🇺🇸Tucson, Arizona, United States